Greenwich LifeSciences, Inc.
NASDAQ:GLSIBiotechnology
-$0.74 today
- Market cap
- $302.08M
- Beta
- 1.38
- P/E (TTM)
- -15.6
- EPS (TTM)
- -$1.49
Volume 0.71M
Average 0.14M
GLSI Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
Greenwich LifeSciences, Inc.NASDAQ: GLSI
Accounts Payables · Q1 FY2026 · quarter ended Mar 2026
Accounts payables growth accelerates
Q1 FY2026 accounts payables of $365.46K (cash outflow) rose 181.9% year over year, ahead of the +161.8% change in trailing-twelve-month accounts payables.
Context
- Accounts payables increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +181.9% holds above the trailing-twelve-month pace of +161.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- 2.07M USD
- Year-over-year change
- +124.9%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.07M | +124.9% |
| FY2024 | 2024-12-31 | 921.22K | +2497.0% |
| FY2023 | 2023-12-31 | 35.47K | — |
| FY2022 | 2022-12-31 | 0 | +100.0% |
| FY2021 | 2021-12-31 | (526.73K) | — |
Accounts Payables vs competitors
How GLSI compares with its peers on the latest reported figures
- Peers report in different currencies, so accounts payables is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +161.8% is the 2nd highest of 7, against a peer median of -48.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $8.98M USD | -41.7% | +53.5% | 7.2% | |
| LTM Mar 2026 | $3.99M USD | -200.8% | — | — | |
| LTM Mar 2026 | $1.93M USD | -198.4% | — | 12.8% | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $1.88M USD | +559.7% | — | 15.7% |
| LTM Mar 2026 | $1.84M USD | +161.8% | — | — | |
| LTM Mar 2026 | $1.2M USD | -56.1% | -3.2% | — | |
| LTM Mar 2026 | CA$1.13M CAD | — | — | — | |
| LTM Mar 2026 | $452.01K USD | — | — | — | |
| LTM Mar 2026 | $307K USD | +89.5% | — | 4.1% | |
| Peer median (excluding GLSI) | — | -48.9% | +25.2% | 10.0% | |
Competitors are the stored peer set for GLSI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (4.57M) | (7.83M) | (8.89M) | (15.79M) | (19.36M) |
| Depreciation & Amortization | 3.61K | 3.61K | 3.61K | 3.61K | 1.78K |
| Deferred Income Tax | (1.19M) | (1.75M) | 0 | 0 | 0 |
| Stock-Based Compensation | 660.58K | 1.74M | 2.38M | 7.25M | 6.8M |
| Change in Working Capital | (385.17K) | (122.27K) | 31.5K | 1.27M | 2.64M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (526.73K) | 0 | 35.47K | 921.22K | 2.07M |
| Other Working Capital | 141.57K | (122.27K) | (3.97K) | 344.11K | 568.12K |
| Other Non-Cash Items | 1.19M | 1.75M | 0 | 0 | 0 |
| Operating Cash Flow | (4.29M) | (6.2M) | (6.48M) | (7.27M) | (9.91M) |
| Capital Expenditures | 0 | (3) | 0 | 3 | 3 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 0 |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 3.11M | 0 | 0 | 4.37M | 12M |
| Common Stock Repurchased | 0 | (7.54M) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (275.15K) | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 2.84M | (7.54M) | 0 | 4.37M | 12M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (1.46M) | (13.74M) | (6.48M) | (2.9M) | 2.09M |
| Free Cash Flow | (4.29M) | (6.2M) | (6.48M) | (7.27M) | (9.91M) |
Greenwich LifeSciences, Inc.
NASDAQ:GLSI
Intrinsic Alpha fair value
Locked
Current Price
$20.58
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.